Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 103

1.

Switching to systemic therapy after locoregional treatment failure: Definition and best timing.

Ogasawara S, Ooka Y, Koroki K, Maruta S, Kanzaki H, Kanayama K, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kato J, Kato N.

Clin Mol Hepatol. 2020 Jan 15. doi: 10.3350/cmh.2019.0021n. [Epub ahead of print] Review.

2.

Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma.

Maeda T, Kanzaki H, Chiba T, Ao J, Kanayama K, Maruta S, Kusakabe Y, Saito T, Kobayashi K, Kiyono S, Nakamura M, Ogasawara S, Suzuki E, Ooka Y, Nakamoto S, Nakagawa R, Muroyama R, Kanda T, Maruyama H, Kato N.

BMC Cancer. 2019 Nov 12;19(1):1088. doi: 10.1186/s12885-019-6322-9.

3.

Superinfection of hepatitis A virus in hepatocytes infected with hepatitis B virus.

Win NN, Kanda T, Ogawa M, Nakamoto S, Haga Y, Sasaki R, Nakamura M, Wu S, Matsumoto N, Matsuoka S, Kato N, Shirasawa H, Yokosuka O, Okamoto H, Moriyama M.

Int J Med Sci. 2019 Sep 20;16(10):1366-1370. doi: 10.7150/ijms.32795. eCollection 2019.

4.

Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan.

Ogasawara S, Ooka Y, Itokawa N, Inoue M, Okabe S, Seki A, Haga Y, Obu M, Atsukawa M, Itobayashi E, Mizumoto H, Sugiura N, Azemoto R, Kanayama K, Kanzaki H, Maruta S, Maeda T, Kusakabe Y, Yokoyama M, Kobayashi K, Kiyono S, Nakamura M, Saito T, Suzuki E, Nakamoto S, Yasui S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato N.

Invest New Drugs. 2019 Jun 6. doi: 10.1007/s10637-019-00801-8. [Epub ahead of print]

PMID:
31172442
5.

Inhibitory effect of Japanese rice-koji miso extracts on hepatitis A virus replication in association with the elevation of glucose-regulated protein 78 expression.

Win NN, Kanda T, Nakamoto S, Moriyama M, Jiang X, Suganami A, Tamura Y, Okamoto H, Shirasawa H.

Int J Med Sci. 2018 Jul 30;15(11):1153-1159. doi: 10.7150/ijms.27489. eCollection 2018.

6.

Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events.

Kanda T, Yasui S, Nakamura M, Nakamoto S, Takahashi K, Wu S, Sasaki R, Haga Y, Ogasawara S, Saito T, Kobayashi K, Kiyono S, Ooka Y, Suzuki E, Chiba T, Maruyama H, Moriyama M, Kato N.

Oncotarget. 2018 Mar 23;9(22):16263-16270. doi: 10.18632/oncotarget.24620. eCollection 2018 Mar 23.

7.

Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis.

Kanda T, Yasui S, Nakamura M, Nakamoto S, Takahashi K, Wu S, Sasaki R, Haga Y, Ogasawara S, Saito T, Kobayashi K, Kiyono S, Ooka Y, Suzuki E, Chiba T, Maruyama H, Imazeki F, Moriyama M, Kato N.

Oncotarget. 2018 Feb 3;9(14):11631-11637. doi: 10.18632/oncotarget.24391. eCollection 2018 Feb 20.

8.

Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature.

Haga Y, Kanda T, Yasui S, Nakamura M, Ooka Y, Takahashi K, Wu S, Nakamoto S, Arai M, Chiba T, Maruyama H, Yokosuka O, Takada N, Moriyama M, Imazeki F, Kato N.

Oncotarget. 2017 Dec 29;9(4):5509-5513. doi: 10.18632/oncotarget.23768. eCollection 2018 Jan 12.

9.

Hepatitis B Virus Genotype C is Predominant in Myanmar.

Nwe Win N, Nakamoto S, Myint Sein M, Moriyama M, Kanda T, Shirasawa H.

Diseases. 2017 Dec 26;6(1). pii: E3. doi: 10.3390/diseases6010003.

10.

Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy.

Nakamoto S, Imazeki F, Kanda T, Wu S, Nakamura M, Yasui S, Tawada A, Mikata R, Chiba T, Arai M, Yokosuka O, Shirasawa H.

Int J Med Sci. 2017 Sep 4;14(11):1088-1093. doi: 10.7150/ijms.20171. eCollection 2017.

11.

Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Could Not Always Predict Early Cirrhosis in Non-Viral Liver Diseases.

Haga Y, Kanda T, Sasaki R, Nakamura M, Takahashi K, Wu S, Yasui S, Arai M, Nakamoto S, Yokosuka O.

Diseases. 2016 Dec 14;4(4). pii: E38. doi: 10.3390/diseases4040038.

12.

Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment.

Ogasawara S, Chiba T, Ooka Y, Suzuki E, Maeda T, Yokoyama M, Wakamatsu T, Inoue M, Saito T, Kobayashi K, Kiyono S, Nakamura M, Nakamoto S, Yasui S, Tawada A, Arai M, Kanda T, Maruyama H, Yokosuka O, Kato N.

Invest New Drugs. 2018 Apr;36(2):332-339. doi: 10.1007/s10637-017-0507-3. Epub 2017 Sep 11.

PMID:
28891038
13.

Overexpression of the androgen receptor in human hepatoma cells and its effect on fatty acid metabolism.

Kanda T, Jiang X, Nakamura M, Haga Y, Sasaki R, Wu S, Nakamoto S, Imazeki F, Yokosuka O.

Oncol Lett. 2017 Jun;13(6):4481-4486. doi: 10.3892/ol.2017.5973. Epub 2017 Apr 3.

14.

Glucose-regulated protein 78 is an antiviral against hepatitis A virus replication.

Jiang X, Kanda T, Haga Y, Sasaki R, Nakamura M, Wu S, Nakamoto S, Shirasawa H, Okamoto H, Yokosuka O.

Exp Ther Med. 2017 Jun;13(6):3305-3308. doi: 10.3892/etm.2017.4407. Epub 2017 Apr 28.

15.

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin.

Kanda T, Nakamura M, Yasui S, Haga Y, Tawada A, Suzuki E, Ooka Y, Takahashi K, Sasaki R, Wu S, Nakamoto S, Arai M, Imazeki F, Yokosuka O.

Biology (Basel). 2017 May 9;6(2). pii: E30. doi: 10.3390/biology6020030.

16.

Serum microRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein are useful tools for liquid biopsy of the patients with hepatitis B virus and advanced liver fibrosis.

Nakamura M, Kanda T, Jiang X, Haga Y, Takahashi K, Wu S, Yasui S, Nakamoto S, Yokosuka O.

PLoS One. 2017 May 5;12(5):e0177302. doi: 10.1371/journal.pone.0177302. eCollection 2017.

17.

Androgen Receptor Could Be a Potential Therapeutic Target in Patients with Advanced Hepatocellular Carcinoma.

Kanda T, Takahashi K, Nakamura M, Nakamoto S, Wu S, Haga Y, Sasaki R, Jiang X, Yokosuka O.

Cancers (Basel). 2017 May 5;9(5). pii: E43. doi: 10.3390/cancers9050043.

18.

Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors.

Kanda T, Yasui S, Nakamura M, Suzuki E, Arai M, Ooka Y, Ogasawara S, Chiba T, Saito T, Haga Y, Takahashi K, Sasaki R, Wu S, Nakamoto S, Tawada A, Maruyama H, Imazeki F, Kato N, Yokosuka O.

Int J Mol Sci. 2017 Apr 25;18(5). pii: E906. doi: 10.3390/ijms18050906.

19.

Interferon induces interleukin 8 and bone marrow stromal cell antigen 2 expression, inhibiting the production of hepatitis B virus surface antigen from human hepatocytes.

Haga Y, Kanda T, Nakamoto S, Nakamura M, Sasaki R, Wu S, Yokosuka O.

Biochem Biophys Res Commun. 2017 May 6;486(3):858-863. doi: 10.1016/j.bbrc.2017.03.150. Epub 2017 Mar 28.

PMID:
28363866
20.

Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines.

Haga Y, Kanda T, Nakamura M, Nakamoto S, Sasaki R, Takahashi K, Wu S, Yokosuka O.

PLoS One. 2017 Mar 21;12(3):e0174153. doi: 10.1371/journal.pone.0174153. eCollection 2017.

Supplemental Content

Loading ...
Support Center